Bio Essence

Bio Essence Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Bio Essence (BIOE) as of Oct 17, 2026 is -37.25. In the previous year, Cash Conversion Cycle (CCC) was -54.84 — a change of -32.07% (higher).

Cash Conversion Cycle

-37.25

YoY

-32.07%

Last updated:

Cash Conversion Cycle (CCC) of Bio Essence is 2025 -37.25 . Cash Conversion Cycle (CCC) of Bio Essence was 2024 -54.84 . It decreases by -32.07% higher compared to the previous year.

The Bio Essence Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
410.71 USD
Jan 1, 2019
257.16 USD
Jan 1, 2020
127.88 USD
Jan 1, 2021
99.99 USD
Jan 1, 2022
166.81 USD
Jan 1, 2023
-35.52 USD
Jan 1, 2024
-54.84 USD
Jan 1, 2025
-37.25 USD
The Bio Essence Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-37.25-32.07%
-54.84+54.40%
-35.52-121.29%
166.81+66.82%
99.99-21.81%
127.88-50.27%
257.16-37.39%
410.71+14.67%
358.18—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Essence Stock analysis

What does Bio Essence do? Bio Essence Corp, trading under the ticker BIOE with ISIN US09090C1053, is a U.S.-based company headquartered in Irvine, California. The company made its initial public offering on March 30, 2022. Bio Essence Corp operates through three subsidiaries: Bio Essence Pharmaceutical, Inc. (BEP), Bio Essence Herbal Essentials Inc. (BEH), and McBE Pharma, Inc. (McBE). BEP functions as an original equipment manufacturer (OEM) for health supplements. BEH serves the practitioners' market with herbal products available in granules, capsules, pills, and tablets, and offers special formulation services to healthcare practitioners. McBE focuses on the development, manufacturing, and sales of prescription drugs. The company provides nutritional supplements, including herbal, diet, and vitamin products, and facilitates direct connections between customers and integrative healthcare practitioners such as dietitians and nutraceutical practitioners. Bio Essence Corp does not specify its sector or industry in the provided information. The company’s business model emphasizes integrated health supplements and research-intensive products, though the nature of its research activities is not detailed. It operates without a publicly disclosed founding year, and no acquisitions or specific product names beyond the subsidiaries are mentioned. The company's operations are centered around its subsidiaries' distinct roles in the health supplement and pharmaceutical markets. Bio Essence is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Essence stock

Cash Conversion Cycle (CCC) of Bio Essence is -37.25 in 2025.

Cash Conversion Cycle (CCC) of Bio Essence changed from -54.84 to -37.25, representing a -32.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Bio Essence since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Bio Essence with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bio Essence

All Key Metrics — Bio Essence